PHARMACEUTICAL 2025

Genelux Corp
Rank 89 of 225



PHARMACEUTICAL 2025

Genelux Corp
Rank 89 of 225

The relative strengths and weaknesses of Genelux Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genelux Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 104% points.The greatest weakness of Genelux Corp is the variable Net Income, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 251%, being 36% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	31,548
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,903
Liabilities, Non-Current	1,539
Other Assets	1,852
Other Compr. Net Income	50
Other Expenses	0
Other Liabilities	0
Other Net Income	1,827
Other Revenues	8.0
Property and Equipment	1,316
Research and Development	18,998
Selling, General and Administrative Expense	12,706

Output Variable	Value in 1000 USD
Assets	34,716
Liabilities	8,442
Expenses	31,704
Revenues	8.0
Stockholders Equity	26,274
Net Income	-29,869
Comprehensive Net Income	-29,844
BaseVar	38,374
ECR before LimitedLiability	127%
Economic Capital Ratio	251%